Stockscreener 앱 받기
70.91
3.76%
-2.77
시간 외 거래:
70.91
전일 마감가:
$73.68
열려 있는:
$72.47
하루 거래량:
1.49M
Relative Volume:
0.62
시가총액:
$9.63B
수익:
$105.82M
순이익/손실:
$-829.61M
주가수익비율:
-10.36
EPS:
-6.8429
순현금흐름:
$-548.92M
1주 성능:
-7.05%
1개월 성능:
+11.93%
6개월 성능:
+11.65%
1년 성능:
+127.20%
1일 변동 폭
$70.30
$73.63
1주일 범위
$70.30
$78.85
52주 변동 폭
$30.81
$80.20
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
70.91 | 10.00B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.92 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.12 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.31 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Wells Fargo | Overweight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokineti - GuruFocus
Cytokinetics EVP Andrew Callos sells $1.11m in stock By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics director Parshall sells $370,400 of CYTK stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP Andrew Callos sells $1.11m in stock - Investing.com
Cytokinetics director Edward Kaye sells $223,171 in shares - Investing.com
Cytokinetics director Parshall sells $370,400 of CYTK stock - Investing.com
Cytokinetics director Edward Kaye sells $223,171 in shares By Investing.com - Investing.com India
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics (CYTK) Launches Myqorzo in Germany for Heart Condition Treatment - GuruFocus
Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy - marketscreener.com
Cytokinetics launches heart drug Myqorzo in Germany By Investing.com - Investing.com Nigeria
Cytokinetics Announces European Launch of MYQORZO® (aficamten) for Obstructive Hypertrophic Cardiomyopathy in Germany Following U.S. Approval - Quiver Quantitative
Cytokinetics launches Myqorzo® (aficamten) in European Union, with first commercial availability in Germany - marketscreener.com
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany - The Manila Times
New heart drug MYQORZO reaches German patients with obstructive HCM - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Why Cytokinetics Inc. Shares Soared - AOL.com
Cytokinetics, Inc. (CYTK) Stock Analysis: Exploring a 36.40% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
What Makes Cytokinetics' MYQORZO Launch a Game Changer - Kavout
CYTK News | CYTOKINETICS INC (NASDAQ:CYTK) - ChartMill
Biotech Catalysts Put Three Small Caps On Watch - Kalkine Media
Cytokinetics Insider Sold Shares Worth $579,075, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (CYTK) CEO trims stake with 7,500-share stock sale - Stock Titan
Citi Calls Cytokinetics, Incorporated (CYTK) a “Top Pick” Among Small-to-Mid Cap Biotech Stocks - Insider Monkey
CYTOKINETICS (CYTK) director awarded shares and new 4,301-share stock option - Stock Titan
Cytokinetics (CYTK) director granted new shares and long-dated stock options - Stock Titan
Cytokinetics (CYTK) director awarded shares and 4,301 stock options - Stock Titan
CYTOKINETICS (CYTK) director receives share grant and 4,301-share option award - Stock Titan
CYTOKINETICS (CYTK) director granted shares and new stock options in Form 4 filing - Stock Titan
Director at Cytokinetics (NASDAQ: CYTK) awarded shares and options - Stock Titan
Director at Cytokinetics (NASDAQ: CYTK) gets new stock and option grants - Stock Titan
Cytokinetics (CYTK) director awarded new stock and option grants - Stock Titan
Cytokinetics (CYTK) director Nancy Wysenski receives stock and 4,301-share option grant - Stock Titan
Cytokinetics (CYTK) investors approve directors, ESPP share increase and auditor - Stock Titan
Cytokinetics to Participate in June Investor Conferences - GlobeNewswire
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
‘You have to be an optimist in drug discovery’ - Scientific American
A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance - Yahoo Finance
Cytokinetics, Incorporated (CYTK) Stock Analysis: A 36% Potential Upside In Biotechnology - DirectorsTalk Interviews
Cytokinetics’s SWOT analysis: biotech stock faces profitability test By Investing.com - Investing.com South Africa
Cytokinetics’s SWOT analysis: biotech stock faces profitability test - Investing.com
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise - TradingView
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $264,915, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to Hold Annual Meeting of Stockholders - The Manila Times
Cytokinetics (CYTK) R&D EVP exercises options and sells 3,500 shares - Stock Titan
Cytokinetics CEO to review performance after May 27 stockholder meeting - Stock Titan
CYTK: MYQORZO outperforms launch targets, with robust uptake, expanding access, and strong pipeline progress - TradingView
CYTK Initiated Coverage by Citigroup -- Price Target Set at $99. - GuruFocus
Cytokinetics Inc stock (US2328281044): pipeline updates keep biotech in focus - AD HOC NEWS
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.89%
자본화:
|
볼륨(24시간):